Association of SGLT2 inhibitors and new-onset dementia in non-diabetic patients with heart failure - PubMed
3 hours ago
- #SGLT2 inhibitors
- #Heart failure
- #Dementia
- SGLT2 inhibitors (SGLT2i) are associated with a lower risk of new-onset dementia in non-diabetic heart failure (HF) patients.
- The study used a large retrospective cohort (TriNetX Research Network, 2016-2025) with 46,049 SGLT2i users and 205,010 non-users, matched to 39,979 pairs.
- Key findings include reduced risks of Alzheimer's disease (HR 0.58), vascular dementia (HR 0.41), and all-cause mortality (HR 0.63) in SGLT2i users.
- Secondary benefits included lower risks of ischemic stroke (HR 0.67) and end-stage kidney disease (HR 0.75).
- The median follow-up was 1.2 years in a population with a mean age of 64 years.